The antiphospholipid antibodies include those responsible for the biological false-positive tests for syphilis, lupus anticoagulant activity and anticardiolipin antibodies (ACA) measured by specific radioimmunoassays. Clinical manifestations that have been associated with antiphospholipid antibodies include arterial and venous thrombosis, thrombocytopenia, recurrent abortion and neurological disease. Although often found in patients who fulfil the usual criteria for systemic lupus erythematosus (SLE), the antibodies and various clinical features may occur at least as frequently, if not more so, in patients who do not have SLE1. Two such patients have been seen over the last year and illustrate the wide clinical spectrum of disorders associated with antiphospholipid antibodies. In this paper current understanding ofthe antiphospholipid antibody syndrome is reviewed and the aetiological significance of the antibodies and the mechanism of action are discussed. In 1975 she developed left-sided hemichorea, which resolved in three months but recurred two years later on the right side. She had two spontaneous first trimester abortions in 1976 and 1978. In 1978 hypertension and proteinuria were found and a renal biopsy revealed diffuse proliferative glomerulonephritis.
Case reports
In 1983 she suddenly developed dysphasia. CT scan showed a left cerebral infarction. No abnormality of neck or intracranial vessels was seen on digital subtraction angiography.
At the time of her cerebral infarction her kaolin partial thromboplastin time (KPTT) was noted to be prolonged, with mixing studies confirming the presence of lupus anticoagulant activity. Anticardiolipin antibodies were detected. She was anticoagulated with warfarin and has remained well since that time. Further details of this case have been published elsewhere2. Plasma from a patient with anticoagulant activity has been shown to block the production of prostacyclin from the endothelium of rat aorta rings. This can be overcome by adding arachidonic acid. Carreras and Vermylen'7 have therefore suggested that the antibodies might crossreact with the phospholipids in the endothelial cell membrane, blocking arachidonic acid release and reducing prostacyclin production, thereby increasing platelet aggregation and thrombosis. An alternative mechanism by which thrombosis may occur is by reduction in fibrinolytic activity. Reduced plasminogen activator release has been demonstrated and it has been suggested that this is the result of immune-complex mediated endothelial cell damage'8. Patient's plasma has also been shown to inhibit pre-kallikrein activity which would also reduce fibrinolysis'9. A further possibility is that the antiphospholipid antibodies may activate platelets by binding to phospholipid in platelet membranes causing aggregation and thrombosis.
Neurological disease
The neurological associations of antiphospholipid antibodies are not confined to thrombotic problems. There are also associations with psychiatric problems and transient abnormalities that are probably the result of some other pathological process.
Chorea is a particular neurological manifestation of the antiphospholipid antibody syndrome suffered by one of our patients. It is a well recognized but rare feature ofSLE with a reported incidence of 1-4% and has been reported both in pregnancy and in isolation. Bouchez20 described 3 cases of chorea and circulating anticoagulant and found a total of 9 cases on review of the literature. More recently Asherson and others2' have described 12 cases ofchorea in SLE and 'lupus-like' disease associated with antiphospholipid antibodies. Chorea generally appeared early in the course of the disease and they noted that, in most patients, there was progression to other neurological disorders, particularly in the 7 out of 9 studied who had positive ACA. The pathogenesis of the chorea is uncertain; CT scans, including 5 taken during an episode of chorea, and one MRI scan taken at the time of chorea were normal. It has also been noted that chorea may disappear spontaneously and that it can occur on different sides in a single patient. These observations suggest that the chorea is due to reversible ischaemia rather than cerebral infarction.
ACAs have been found in severe Guillain-Barre syndrome with a statistically significant association of IgA ACA with severe disease22. The authors felt that this suggested a pathogenetic role in GuillainBarre syndrome, though they acknowledged that the antibodies might represent a secondary phenomenon resulting from the destruction ofmyelin. It is possible that certain antiphospholipid antibodies may crossreact with epitopes on cerebral phospholipids such as sphingomyelin8. Optic neuritis and myelopathy in association with ACA in SLE have also recently been reported23.
Recurrent abortion
Recurrent spontaneous abortion, as in our first case, has been associated with antiphospholipid antibodies. In a study of 43 women with SLE and other autoimmune disorders, 23 had a history of recurrent fetal loss; 16 of these had raised ACA and/or lupus anticoagulant activity. The association between antiphospholipid antibodies and fetal loss was statistically significant24. Lockshin and others25 have found an association between mid-pregnancy fetal distress and raised ACA. The affected patients included 2 without SLE. A retrospective study has also been performed looking at the outcome of pregnancies in women with biologically false-positive tests for syphilis. A high rate of stillbirth, neonatal and infant death was found in those pregnancies reaching maturity (28 weeks) 26 .
Examination of placentas of aborted fetuses shows multiple areas ofinfarction, though the degree of infarction has sometimes been felt to appear inadequate to account for fetal death27, and it has been suggested that a deficiency of prostacyclin production by placental vessels may cause increased platelet aggregation, reduced blood flow, placental infarction and fetal distress" ".
Renal disease and thrombocytopenia Renal disease in patients with SLE and circulating anticoagulant has been investigated by Glueck and others in Cincinatti28. They looked at the renal biopsies of 18 patients and described striking glomerular and arteriolar thrombosis in patients with circulating anticoagulant. A group of patients with SLE but no circulating anticoagulant served as controls.
Thrombocytopenia is another feature of the antiphospholipid antibody syndrome. In Boey's study" the platelet count was less than 100 x 109/l in 9 out 31 patients with lupus anticoagulant activity but only 1 out of 29 without. Harris and others29 have confirmed this in a larger series of 116 patients with SLE and other autoimmune disease, ofwhom 43 were thrombocytopenic, 70% with raised ACA. There was a correlation between platelet and ACA levels. Of those patients with antibody levels more than 7 standard deviations above the mean, 75% had a history of thrombocytopenia. An association between idiopathic thrombocytopenia and raised ACA has also been found30. It is possible that the antibodies bind with platelet membrane phospholipids and cause enhanced uptake and destruction of platelets by the reticulo-endothelial system. Another recently described association with antiphospholipid antibodies is livedo reticularis, which Hughes3' and others have noted to occur with a high incidence of hypertension and stroke.
Treatment
The optimal treatment of patients who have antiphospholipid antibodies is the least well studied aspect of the syndrome. Patients with recurrent thrombosis should be treated with long-term oral anticoagulants. There have been several reports of patients having recurrent thrombotic episodes after stopping anticoagulants32'33. Antiplatelet drugs seem a theoretically logical adjunct to anticoagulants but, although they have been used as part of the treatment ofpatients with various features of the syndrome in many studies and reported cases, there does not seem to have been any controlled trial of their use. Steroid therapy has been found to be of value in recurrent abortion and where oral anticoagulants are contraindicated. Using prednisolone in conjunction with low-dose aspirin, Lubbe and others34 reported a successful outcome of pregnancy in 5 out of 6 women with SLE, lupus anticoagulant activity and a history of recurrent intrauterine death. However, this regimen does not completely rectify the underlying pathophysiology of the disorder; Branch and others35 have reported fetal death in spite of correction of the KPTT. They also noted that pre-eclampsia developed in all patients who gave birth to live infants, there being fetal growth retardation in 3 out of 5 cases. They emphasized the need for meticulous antenatal care.
Severe steroid side effects have been described in almost all patients treated, even by those advocating that 'it is no longer justified to withhold treatment' where there is a history of recurrent fetal loss in association with lupus anticoagulant27. Immunosuppressive therapy, including steroids, has been shown to decrease lupus anticoagulant activity and ACA levels in many studies, but the clinical benefit of lowering these levels seems uncertain since patients have sometimes been noted to deteriorate in spite of this reduction. Plasmapheresis combined with steroids and/or azathioprine lowers the ACA levels in the majority of patients studied; however, since the antibodies appear to remain elevated for many years in the absence of therapy, it is suggested that any immunosuppressive therapy is likely to need to be prolonged to maintain low levels'.
Conclusion
The bulk of the literature on the antiphospholipid antibody syndrome comprises descriptions of clinical associations of the antibodies. A cause and effect relationship has not been proven. The possibility remains that the antibodies represent epiphenomena, having no direct role in the development of the conditions reported. However, there does appear to be a strong association between the antibodies and a wide diversity of diseases, some of which -particularly the thrombotic disorders -are amenable to preventive therapy. The population involved includes many young adults in whom the consequences of repeated thrombotic episodes may be particularly catastrophic.
A widely available investigation, namely the KPTT, can be used as a screening procedure even in the absence of local facilities for specific assay of antiphospholipid antibodies. Knowledge of the presence of the antibodies should modify treatment, particularly its duration. We therefore suggest that antiphospholipid antibodies should be sought in otherwise unexplained occlusive thrombotic disease, including myocardial infarction and stroke, in recurrent fetal loss and thrombocytopenia, in a much wider range of patients than those with SLE in whom they were first recognized.
